Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for levofloxacin
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levofloxacin or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on levofloxacin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Use of fluoroquinolones to treat paediatric cases of multidrug-resistant tuberculosis could affect the emergence of resistance to this class of drugs. Our aim was to estimate the incidence of, and risk factors for, invasive pneumococcal disease caused by fluoroquinolone-resistant Streptococcus pneumoniae (...) in children in South Africa.21,521 cases of invasive pneumococcal disease were identified by active national surveillance between 2000 and 2006, with enhanced surveillance at 15 sentinel hospitals in seven provinces introduced in 2003. We screened 19,404 isolates (90% of cases) for ofloxacin resistance and measured levofloxacin minimum inhibitory concentrations (MICs) for all isolates that were ofloxacin resistant. Non-susceptibility to levofloxacin was defined as an MIC of 4 mg/L or more. Nasopharyngeal
Levofloxacin for acute exacerbations of chronic bronchitis Levofloxacin for acute exacerbations of chronic bronchitis | Therapeutics Initiative Independent Healthcare Evidence > > Levofloxacin for acute exacerbations of chronic bronchitis Background Information of the Condition Chronic bronchitis is a subset of chronic obstructive pulmonary disease defined by a productive cough for at least 3 months in duration in each of 2 consecutive years, which may include an acute exacerbation of increased (...) sputum production and purulence, and increased dyspnea. An increased respiratory rate and wheezing, lethargy and elevated temperature are usually indicative of an acute exacerbation of chronic bronchitis, which is usually caused by a virus. Measurement of expiratory flow volume is recommended along with oxygen saturation in moderate to severe cases, whereas sputum cultures are not routinely recommended. Drug (Product Monograph) , Category: Levofloxacin, the L-isomer of the racemate ofloxacin
Levofloxacin for community acquired pneumonia Levofloxacin for community acquired pneumonia | Therapeutics Initiative Independent Healthcare Evidence > > Levofloxacin for community acquired pneumonia Background Information of the Condition Pneumonia is the leading cause of death from infection, particularly among elderly and hospitalized patients. Diagnosis is based on history, co-morbidities, physical findings, and chest x-ray. S. pneumoniae accounts for up to 50% of community-acquired (...) pneumonia caused by bacteria. Drug (Product Monograph) Category: Levofloxacin, the L-isomer of the racemate ofloxacin, is a member of the fluoroquinolone class of antibiotics. Mechanism of Action: Levofloxacin exerts its action by inhibiting the bacterial topoisomerases II (DNA gyrase) and topoisomerases IV which interferes with bacterial DNA replication, transcription, repair, and recombination. Indications: Levofloxacin is indicated for the treatment of adults with upper and lower respiratory tract
Levofloxacin for acute bacterial sinusitis Levofloxacin for acute bacterial sinusitis | Therapeutics Initiative Independent Healthcare Evidence > > Levofloxacin for acute bacterial sinusitis Background Information of the Condition Acute bacterial sinusitis is a common, usually self-limited condition often associated with allergies and environmental irritants, as well as co-infection with viruses and fungi. Acute bacterial sinusitis is 200 times less common than viral rhinosinusitis. Symptoms (...) and signs suggesting bacterial, as opposed to viral sinusitis include purulent nasal discharge in combination with facial pain and maxillary toothache, facial swelling and tenderness. Most diagnoses are based on history and physical examination as opposed to laboratory cultures and sinus xrays, which are considered unreliable. Drug (Product Monograph) Category: Levofloxacin is a fluoroquinolone class, broad-spectrum antibacterial agent. It is the L- isomer of the racemate, ofloxacin. Mechanism of Action
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis Saad R J, Schoenfeld P, Kim H M, Chey W D CRD summary This review concluded that a 10-day (...) course of levofloxacin-based triple therapy is more effective and better tolerated than a 7- day course of bismuth-based quadruple salvage therapy for the treatment of persistent Helicobacter pylori infection. However, it is unclear how reliable the conclusions are, given the reliance on a small number of variable studies and the lack of a validity assessment. Authors' objectives To compare levofloxacin-based triple therapy and bismuth-based quadruple salvage therapy for the treatment of persistent
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial and is not a recommended intervention.We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start (...) of chemotherapy until the resolution of neutropenia. Patients were stratified according to their underlying disease (acute leukemia vs. solid tumor or lymphoma).An intention-to-treat analysis showed that fever was present for the duration of neutropenia in 65 percent of patients who received levofloxacin prophylaxis, as compared with 85 percent of those receiving placebo (243 of 375 vs. 308 of 363; relative risk, 0.76; absolute difference in risk, -20 percent; 95 percent confidence interval, -26 to -14
Iquix (Levofloxacin) Ophthalmic Solution Drug Approval Package: Iquix (Levofloxacin) NDA #021571 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Iquix (Levofloxacin) Ophthalmic Solution Company: Santen, Inc. Application No.: 021571 Approval Date: 3/01/2004 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: October 262004 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information
Levaquin (Levofloxacin) Oral Solution Drug Approval Package: Levaquin (Levofloxacin) NDA #021721 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Levaquin (Levofloxacin) Oral Solution Company: Ortho McNeil Pharmaceutical, Inc. Application No.: 021721 Approval Date: 12/21/2004 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: April 202007 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. Large variations exist among hospitals in the use of treatment resources for community-acquired pneumonia (CAP). Lack of a common approach to the diagnosis and treatment of CAP has been cited as an explanation for these variations.To determine if use of a critical pathway improves the efficiency of treatment (...) rule to guide the admission decision, levofloxacin therapy, and practice guidelines.Effectiveness of the critical pathway, as measured by health-related quality of life on the Short-Form 36 Physical Component Summary (SF-36 PCS) scale at 6 weeks; and resource utilization, as measured by the number of bed days per patient managed (BDPM).Quality of life and the occurrence of complications, readmission, and mortality were not different for the 2 strategies; the 1-sided 95% confidence limit
Pharmaceutical economics & health policy: economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin Pharmaceutical economics & health policy: economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin Pharmaceutical economics & health policy: economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin Palmer C S, Zhan C, Elixhauser A, Halpern M T, Rance L, Feagan B G, Marrie T J (...) of the Pneumonia Severity Scoring Index (PSSI) to avoid unnecessary hospitalisation of CAP patients; criteria for switching from intravenous to oral therapy to reduce intravenous antibiotic use and length of stay (LOS); and the use of levofloxacin as the antibiotic, with the aim of having fewer patients treated with more than one antibiotic. In the conventional therapy arm, decisions on admission to the hospital, choice of antibiotic (excluding levofloxacin), switching from intravenous to oral antibiotics, use